Vaccines Show Greater than Ninety Percent Efficacy

Posted on by

“It’s not vaccines that save people; it’s vaccinations that will actually save people.” Edward Kelly, director of the WHO’s work on service delivery and safety

Biotechnology firm Moderna announced this week that preliminary results from large scale trials indicated that its coronavirus vaccine candidate demonstrated nearly 95 percent efficacy at preventing the illness.  This news comes on the heals of Pfizer’s announcement last week of it coronavirus vaccine candidate showed 95 percent efficacy (94 percent for adults over 65 years).

Efficacy refers to the performance of a treatment under ideal and controlled circumstances, and effectiveness is performance under real-world conditions. Clinical trials take place in a controlled environment to test if a vaccine is safe and if it works.

The efficacy rate means that COVID-19 symptoms were prevented for more than 90 percent for Pfizer’s coronavirus candidate and near 95 percent for Moderna’s candidate of participants who received the vaccine.

Pfizer plans to seek emergency use authorization for the vaccine, the company said.  This leave Pfizer’s vaccine on track to go into distribution by the end of the year if health regulators at the FDA permit.

Public health officials warn that the development of an effective COVID-19 vaccine represents the beginning of the challenge to vaccinate the world. “It’s not vaccines that save people; it’s vaccinations that will actually save people,” Edward Kelly, director of the WHO’s work on service delivery and safety, said.

A few of the significant challenges to vaccinate the world relate to vaccine supply, storage and distribution.  For example, Pfizer’s experimental vaccine requires ultracold storage conditions of about minus-70 degrees Celsius to ensure it remains effective.  While, Moderna’s vaccine can be kept at refrigerator temperatures for a month and frozen at minus-20 degrees Celsius for up to six months.

Additionally, there appears to be a steady reluctance among Americans and people across the globe to take the vaccine.  Convincing Americans that coronavirus vaccines are safe and effective will be another challenge thanks to the politicization of the vaccine development process by both sides of the aisle.

The U.S. Food and Drug Administration (FDA) will ultimately decide whether to authorize vaccines from Pfizer, Moderna and other candidates currently in large scale trials based on safety and effectiveness results that have been carefully reviewed by both government and independent health experts.

Health care workers should be given the highest priority to receive the vaccine and given to workers in essential industries, people with certain medical conditions, and people age 65 and older.

Bottom line, no vaccine is 100% effective, and whatever protection vaccines may provide, people should continue to wear masks, maintain social distancing, wash hands frequently, not touch their face and avoid crowded indoor gatherings until public health officials determine and the infection numbers demonstrate that the virus is under control.

References:

  1. https://www.washingtonpost.com/world/2020/11/16/who-vaccine-moderna-pfizer/
  2. https://www.wsj.com/articles/pfizers-covid-19-vaccine-95-effective-in-final-results-company-to-seek-approval-within-days-11605699996
  3. https://time.com/5907908/biden-administration-covid-19/?utm_source=twitter&utm_medium=social&utm_campaign=editorial&utm_term=health_covid-19&linkId=104044772
Advertisements